Evofem Biosciences, Inc. (EVFM): Capital Expenditures
$5.0K
Year ended 2025-12-31
$5.0K
Trailing 12 months to 2026-06-30
-75.5%
3-year compound annual growth
-70.5%
5-year compound annual growth
-31.7%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.0K | -64.3% | 2026-03-11, From 2025-01-01 |
| 2024-12-31 | $14.0K | +250.0% | 2026-03-11, From 2024-01-01 |
| 2023-12-31 | $4.0K | -98.8% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $341.0K | -88.4% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $2.94M | +30.4% | 2023-04-27, From 2021-01-01 |
| 2020-12-31 | $2.25M | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $164.0K | n/m | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $7.0K | +16.7% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $6.0K | n/a | 2019-03-01, From 2017-01-01 |
| No annual figure between 2015-12-31 and 2017-12-31. | |||
| 2015-12-31 | $226.1K | n/m | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | $18.1K | -14.6% | 2017-03-23, From 2014-01-01 |
| 2013-12-31 | $21.2K | n/a | 2016-03-29, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $5.0K | -64.3% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $16.0K | -92.8% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $47.0K | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $246.0K | -63.4% |
| Alumis Inc. (ALMS) | 2025-12-31 | $653.0K | -62.3% |
| uniQure N.V. (QURE) | 2025-12-31 | $439.0K | -87.0% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $1.04M | -67.0% |
| Celularity Inc (CELU) | 2024-12-31 | $161.0K | -84.6% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $177.0K | +168.2% |
Compare EVFM, CASIF, SLGL, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗